{Reference Type}: Journal Article
{Title}: Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypes.
{Author}: Li MY;Liu YH;Wei F;Zhang P;Sun XD;Wang M;Du XH;Ye JF;Qiu W;Shi XJ;Ji B;Wang YC;Jiang C;Chai WG;Huang B;Liu XK;Chen QM;Fu Y;Hu XT;Chen LG;He JX;Chai KY;Gou ZM;Yang T;Wang GY;Jiang YF;Fan ZQ;Lv GY;
{Journal}: Genomics
{Volume}: 116
{Issue}: 5
{Year}: 2024 Jun 18
{Factor}: 4.31
{DOI}: 10.1016/j.ygeno.2024.110889
{Abstract}: Cholangiocarcinoma (CCA) is widely noted for its high degree of malignancy, rapid progression, and limited therapeutic options. This study was carried out on transcriptome data of 417 CCA samples from different anatomical locations. The effects of lipid metabolism related genes and immune related genes as CCA classifiers were compared. Key genes were derived from MVI subtypes and better molecular subtypes. Pathways such as epithelial mesenchymal transition (EMT) and cell cycle were significantly activated in MVI-positive group. CCA patients were classified into three (four) subtypes based on lipid metabolism (immune) related genes, with better prognosis observed in lipid metabolism-C1, immune-C2, and immune-C4. IPTW analysis found that the prognosis of lipid metabolism-C1 was significantly better than that of lipid metabolism-C2 + C3 before and after correction. KRT16 was finally selected as the key gene. And knockdown of KRT16 inhibited proliferation, migration and invasion of CCA cells.